Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.34 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.34 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18589278 | 0.85 | KCNA4 (0.34) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1108447 | 0.85 | EPHX1 (0.42) | EPHX1KCNA4KCNA1KCNAB1 | |
| SCHEMBL9788202 | 0.85 | KCNA4 (0.30) | KCNA4KCNA1KCNAB1 | |
| Methane SCHEMBL9788186 | 0.83 | EPHX1 (0.41) | EPHX1 | |
| SCHEMBL8327277 | 0.81 | EPHX1 (0.34) | EPHX1 | |
| SCHEMBL14890932 | 0.81 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL15976129 | 0.79 | KCNA4 (0.31) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL10015857 | 0.78 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL20434892 | 0.77 | POLB (0.38) | EPHX1KCNA4KCNA1KCNAB1 | |
| SCHEMBL9788252 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8816099-B2 | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof | NOF CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20110245509-A1 | POLYFUNCTIONAL POLYOXYALKYLENE COMPOUND, AND PRODUCING METHOD AND INTERMEDIATE THEREOF | NOF CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-7563291-B2 | Demulsifiers for mixtures of middle distillates with fuel oils of vegetable or animal origin and water | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| EP-1584631-B1 | Copolymerizable polyethylenglycol macromonomers, their preparation and use | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | EPHX1 3933/4885KCNA4 4839/4885KCNA1 4858/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | EPHX1 3933/4885KCNA4 4839/4885KCNA1 4858/4885 |
| US-20110245509-A1 | POLYFUNCTIONAL POLYOXYALKYLENE COMPOUND, AND PRODUCING METHOD AND INTERMEDIATE THEREOF | OXER1, ODC1, SQLE | EPHX1 443/4885KCNA4 2772/4885KCNA1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.